Truist raised the firm’s price target on Praxis Precision (PRAX) to $500 from $360 and keeps a Buy rating on the shares. Vormatrigine reported 100% median seizure reduction at week 8, which was sustained through week 16 in full Phase 2 RADIANT study, and the results significantly de-risk forthcoming Phase 2/3 POWER1 in the first half of FY26, the analyst tells investors in a research note. Planned Relutrigine NDA submission, possibly as early as Q1, places the drug significantly ahead of bexicaserin in Developmental and Epileptic Encephalopathies, or DEE, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $353 from $251 at TD Cowen
- Praxis Precision provides clinical updates at AES annual meeting
- Praxis Precision price target raised to $315 from $304 at Needham
- Praxis Precision price target raised to $507 from $499 at BTIG
- Promising Clinical Data and Strategic Developments Drive Buy Rating for Praxis Precision Medicines